The biotechnology sector, as measured by the XBI ETF, experienced a significant downturn of -4.24% during the regular trading session. This decline coincided with a broader market sell-off, with major indices like the S&P 500 and Nasdaq also closing in negative territory. The negative market sentiment was largely attributed to renewed concerns about inflation and geopolitical tensions. While no single, major catalyst specific to the biotech sector was identified, the sector's inherent volatility likely amplified the impact of the overall market downturn.